ABSTRACT
The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDI) for mechanism based inactivators of human cytochrome P450 enzymes was examined using eight human P450 selective marker activities in pooled human liver microsomes. These data were combined with other parameters (systemic C max , estimated hepatic inlet C max , fraction unbound, in vivo P450 enzyme degradation rate constants estimated from clinical pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared to in vivo DDI gathered from clinical studies reported in the scientific literature. In general, the use of unbound systemic C max as the inactivator concentration in vivo yielded the most accurate predictions of DDI with a mean fold error of 1.64. Abbreviated in vitro approaches to identifying mechanism based inactivators were developed. Testing potential inactivators at a single concentration (IC 25 ) in a 30 min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P450 marker activities readily identified those compounds known to be mechanism-based inactivators, and represents an approach that can be employed with greater throughput. Measurement of decreases in IC 50 occurring with a 30 min preincubation with liver microsomes and NADPH were also useful in identifying mechanism-based inactivators, and the IC 50 measured after such a preincubation was highly correlated with the k inact /K I ratio measured after a full characterization of inactivation. Overall, these findings support the conclusion that P450 in vitro inactivation data are valuable in predicting clinical DDI that can occur via this mechanism.
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INTRODUCTION
The prediction of drug-drug interactions (DDI) using in vitro enzyme kinetic data has been an area of increasing advances and sophistication. This has proven to be a valuable endeavor because DDI remain an important issue in clinical practice and the discovery and development of new drugs. The earlier that the potential for DDI can be identified in new compounds being studied as potential drugs, the greater the likelihood that this deleterious property can be removed through improved design of the molecule. Also, for those compounds already undergoing clinical trials, in vitro DDI data can be leveraged in the design of adequate and appropriate clinical DDI studies. With our increased understanding of drug metabolizing enzymes and their roles in the metabolism of specific drugs, a mechanistic approach to assessing DDI can be taken. The results of clinical DDI studies with one drug can be extrapolated to other drugs that are cleared by the same enzyme.
The alteration of drug metabolizing enzyme activities can occur by three main mechanisms: reversible inhibition, mechanism-based inactivation, and induction. Confidence in quantitatively extrapolating in vitro results to in vivo varies with these mechanisms. For reversible inhibition mechanisms, recent advances in our ability to predict the magnitude of DDI from in vitro inhibition data have been made such that for cytochrome P450 enzymes, increases in exposure can be predicted within 2-fold Brown, et al., 2005; Ito, et al., 2005) . Through the use of human hepatocytes in culture, enzyme inducers can be readily identified (Silva and Nicholl-Griffith, 2002) . However the magnitude of predicted DDI for inducers varies with the source of individual hepatocytes. Recently, in vitro induction data from an immortalized human hepatocyte line, which gives a robust and reliable response, has been demonstrated to yield quantitative predictions of CYP3A induction-based DDI in vivo (Ripp, et al, 2006) .
For mechanism-based inactivators, there have been some reports describing the prediction of in vivo DDI, particularly for CYP3A (Galetin, et al., 2006; Wang, et al., 2004; Ito, This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on November 8, 2006 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from Yamano, et al., 2001; Mayhew, et al., 2000; Kanamitsu, et al., 2000) as well as one analysis for CYP2D6 (Venkatakrishnan and Obach, 2005) . Compared to reversible inhibition, there are some added complexities regarding the prediction of DDI from inactivation data. The design and conduct of in vitro inactivation studies are more complex than reversible inhibition studies, in that experiments require two-steps (preincubation with inactivator followed by dilution and incubation to measure the standard marker activity) and several incubation times are needed to generate inactivation rate constants (k inact ). For extrapolation to in vivo, knowledge of the in vivo rate of degradation of the target enzyme in human is needed. Such a value cannot be measured directly, forcing the use of in vitro data in human hepatocytes, animal data (Mayhew, et al., 2000) , or data modeled from human pharmacokinetic studies of de-induction or recovery following inactivation (Faber and Fuhr, 2004; Venkatakrishnan and Obach, 2005; Takanaga, et al., 2000; Greenblatt, et al., 2003) , and thus greater uncertainty is introduced.
The primary objectives of this work are two fold: (1) to devise a simplified in vitro approach whereby mechanism-based inactivators of P450 enzymes can be identified, and (2) to determine if there is a reliable method that can be used to predict the magnitude of DDI from in vitro inactivation data across multiple P450 enzymes.
This article has not been copyedited and formatted. The final version may differ from this version. Eggler. Other reagents were obtained from common commercial suppliers.
Single Point Inactivation and IC 50 Shift Experiments. Pooled human liver microsomes (0.3 to 2 mg/ml, depending on which enzyme was assessed) were incubated with inactivators, and MgCl 2 (3.3 mM) in potassium phosphate buffer (100 mM, pH 7.4) in the absence and presence of NADPH (1.3 mM). In single point inactivation experiments, the concentration of the inactivator used was 10-fold that which gave 25% inhibition when tested under reversible inhibition conditions. (Thus, after dilution of 10X into the subsequent activity assay, the concentration in the minus NADPH control will be at IC 25 .) In IC 50 shift experiments, multiple concentrations of inactivators were used such that the range included the concentration that was 10-times the IC 50 measured for reversible inhibition. (Thus, after dilution of 10X into the subsequent activity assay, the concentrations in the minus NADPH controls will span IC 50 .) The inactivators were delivered in solvent such that the final solvent concentration was less than 1% (v/v). These preincubations (i.e. the "Inactivation Incubation") were carried out for 30 min at 37 o C. For highly efficient inactivators, a 30 min preincubation time will exceed the time over which the inactivation is first order (i.e. log-linear). However, the selection of a 30 min preincubation period was made to ensure that even weak inactivators could be identified (i.e. to avoid false negatives). Vehicle controls were run to account for any decrease in enzyme activity caused by incubation under these conditions. After the inactivation incubation, a portion of the inactivation mixture (0.02 ml) was added to a mixture containing a standard cytochrome P450 substrate in This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on November 8, 2006 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from 0.18 ml potassium phosphate buffer (100 mM, pH 7.4) containing MgCl 2 (3.3 mM) and NADPH (1.3 mM) for measurement of P450 activities (i.e. the "Activity Incubation"). The substrates used and their concentrations are listed in Table 1 . Substrate concentrations used were proximal to K M values. Incubations were carried out and samples analyzed by HPLC-MS using previously described methods (Walsky and Obach, 2004) .
Single point inactivation data were analyzed by comparing the % inhibition measured when the inactivator was preincubated for 30 min in the presence of NADPH vs that in the absence of NADPH:
Inactivation Kinetic Experiments to Determine K I and k inact . Inactivation kinetic experiments were conducted in a manner similar to that described above. In the inactivation preincubation, various concentrations of inactivator were incubated at 37 o C with pooled human liver microsomes (0.3 to 2 mg/ml, depending on which enzyme was assessed), MgCl 2 (3.3 mM), NADPH (1.3 mM), in potassium phosphate buffer (100 mM, pH 7.4). At six timepoints, aliquots of the inactivation preincubation mixture (0.02 ml) were removed and added to a mixture containing a standard cytochrome P450 substrate, MgCl 2 (3.3 mM), NADPH (1.3 mM), in potassium phosphate buffer (100 mM, pH 7.4) at 37 o C. The substrates used were those described above at concentrations approximately 10-times the K M (Table 1) . To determine k obs values, the decrease in natural logarithm of the activity over time was plotted for each inactivator concentration, and k obs values were described as the negative slopes of the lines. Inactivation kinetic parameters were determined using non-linear regression of the data to the following expression: Predictions of Drug Interactions. The potential for an inactivator to cause an increase in exposure to a drug due to inactivation of hepatic enzymes was assessed using the following equation (Mayhew, et al., 2000) :
The terms are defined as follows: AUC i /AUC is the predicted ratio of in vivo exposure of a CYP cleared drug with coadministration of the inactivator vs that in control state, f m(CYP) is the fraction of total clearance of the drug to which the affected CYP enzyme contributes, k deg is the first-order rate constant of in vivo degradation of the affected CYP enzyme, k inact is the theoretical maximum inactivation rate constant at infinite inactivator concentration as assessed in vitro, K I is the inactivator concentration yielding a measured inactivation rate at half of k inact , and [I] in vivo is the in vivo concentration of the inactivator. For CYP3A, the impact on extraction by the intestine also needs to be accounted for, by including a term for the effect on CYP3A in the intestine (Wang, et al., 2004) :
This article has not been copyedited and formatted. The final version may differ from this version. The following values were used for the parameters needed for equations 3 and 4:
Fraction of the Affected Drug Metabolized by Cytochrome P450s (f m(CYP) ):
Values for the fraction of the affected drug metabolized by the CYP enzyme that is inactivated were previously reported = 0.95 was used based on estimates from in vitro data (Hesse, et al., 2000) and for caffeine a value of f m(CYP1A2) = 0.95 was made using a combination of quantitative human metabolism data reported from control subjects receiving radiolabelled drug (Rodopoulos, et al., 1995) and in vitro data describing P450 enzymes involved in metabolic pathways (Ha, et al., 1996) .
Concentration of the Inactivator In Vivo ([I]
). For the term [I], described as the concentration of inactivator available to the enzyme, the systemic steady-state C max , the systemic steady-state unbound C max (defined as f u • C max ), and the estimated unbound steady-state C max at the inlet to the liver (i.e. C max,u,inlet ; Kanamitsu, et al., 2000) as:
This article has not been copyedited and formatted. The final version may differ from this version. in which D is the dose of the inactivator, k a is the oral absorption rate constant of the inactivator, F a is the fraction of the inactivator absorbed following oral administration, C max is the systemic steady-state maximum concentration of the inactivator, f u is the unbound fraction of inactivator in plasma, and Q h is hepatic blood flow (1450 ml/min).
For CYP3A, the concentration of the inactivator in the enterocyte during absorption ([I] g ) was also considered, and defined as (Rostami-Hodjegan and Tucker, 2004) :
Parameters are the same as described above, with Q g representing enterocytic blood flow (248 ml/min). was used based on the kinetics of de-induction of the oral clearance of verapamil (Fromm et al., 1996) , general clinical pharmacologic understanding of the kinetics of induction and de-induction of CYP3A (Lin, 2006; Thummel, et al., 2000) additionally supported by in vitro estimates of CYP3A turnover in primary human hepatocytes using pulse-chase methods (Pichard et al., 1992) .
In Vivo CYP Degradation Rate Constants (k deg
This article has not been copyedited and formatted. The final version may differ from this version. For the other enzymes (CYPs 2B6, 2C9, 2C19), a mean value of the above described estimates for hepatic CYPs (0.00026 min -1 ) was used since clinical pharmacokinetic data to support similar calculations were not available.
In addition, empirical predictions of the magnitude of DDI were explored using IC 50 values measured following a 30 min preincubation of inactivator, human liver microsomes, and NADPH. Equations used for these predictions were those previously described :
and for CYP3A:
in which IC 50 is the value measured in an activity assay after the inactivator had been preincubated for 30 min with microsomes and NADPH.
Accuracies of prediction methods were assessed using the geometric mean fold error: 
RESULTS
Characterization of Single Point Inactivation. Compounds known to be inactivators for various human CYP enzymes were incubated in an inactivation preincubation at a single concentration representing 10-fold of the concentration known to cause 25% inhibition in the activity incubation. These same compounds were also tested for the other CYP enzymes for which it had not been demonstrated to cause inactivation. This concentration was selected because, in theory, it should be at the most sensitive point for detecting a mechanism-based inactivator (refer to Figure 1 ). The data showing the percent decrease in activity caused by a 30 min incubation of inactivators in the presence of NADPH, vs that in the absence of NADPH are shown in Table 2 .
With the exception of ticlopidine/CYP2C19 and rotonavir/CYP3A, for those combinations where inactivation was expected the percent decrease in activity was at least 30%. These include furafylline and zileuton (CYP1A2, Racha, et al., 1998; Lu, et al., 2003) , ticlopidine, methyl phenethyl piperidine (a.k.a. PPP), and thioTEPA (CYP2B6; Richter, et al., 2004; Chun, et al., 2000) , desethylamiodarone (CYP2C8; Polasek, et al., 2004) , tienilic acid (CYP2C9; Melet, et al., 2003) , methylenedioxymethamphetamine (MDMA) and paroxetine (CYP2D6; Bertelsen, et al., 2003; Heydari, et al., 2004), and diltiazem, erythromycin, and verapamil (CYP3A; Wang, et al., 2004; Mayhew, et al., 2000; McConn, et al., 2004; Ernest, et al., 2005) . With a few exceptions (e.g. desethylamiodarone, thioTEPA), these compounds did not show appreciable inactivation for other CYP enzymes. As a negative control, montelukast, which potently inhibits several P450 enzymes (Walsky, et al., 2005) , did not demonstrate inactivation for any of the enzymes. Ticlopidine showed only an 11% decrease in CYP2C19 activity when incubated in the presence of NADPH. This could be partially due to the fact that the incubation time for assessing CYP2C19 S-mephenytoin hydroxylase activity (40 min) is longer than the 30 min inactivation incubation time, which would be expected to blunt any observable difference. Thus, a decrease in activity of 15% was identified as a cutoff value for identifying inactivators for CYP enzymes, except for CYP2C19 for which a cutoff value of 10% was identified.
This article has not been copyedited and formatted. The final version may differ from this version. was measured. Inactivators were incubated at several concentrations spanning the value of 10 times the reversible inhibition IC 50 for 30 min in the presence or absence of NADPH, followed by a 10-fold dilution into an activity assay incubation. A list of the IC 50 values generated with and without NADPH in the inactivation incubation is in Table 3 and an example is shown in Figure 2 (panel A). The range of IC 50 shifts spanned from a >800-fold decrease (inactivation of testosterone 6β-hydroxylase by erythromycin) to 1.6-fold (inactivation of midazolam 1'-hydroxylase by ritonavir).
Inactivation Kinetics. Values for k inact and K I were measured for those compounds demonstrating IC 50 shifts, and these are listed in Table 4 , with an example shown in Figure 2 . (Refer to the Supplemental Information for plots for all of the inactivators.) A practical limit for measuring k inact values appears to be about 0.005/min, and depends to some extent on the enzyme being studied. Based on k inact values alone, the compounds with the greatest capacity to inactivate various CYP enzymes were ritonavir (CYP3A), MDMA (CYP2D6), ticlopidine (CYP2B6), and tienilic acid (CYP2C9). When the potency is also included to generate k inact /K I ratios, the compounds with the greatest capability to inactivate CYP enzymes are ritonavir (CYP3A), ticlopidine (CYP2B6), tienilic acid (CYP2C9), paroxetine (CYP2D6), and furafylline (CYP1A2).
Comparing values for k inact /K I and the IC 50 , the shifted IC 50 , and the fold shift in IC 50 revealed that the greatest correlation existed with the shifted IC 50 (Figure 3) . A correlation also existed between the shifted IC 50 and K I , which may indicate that the shifted IC 50 contains elements of the inactivator potency. This indicates that the fold change in IC 50 alone is not the most important predictor of the efficiency of an inactivator, but rather what the potency is after conducting a 30 min incubation with the inactivator prior to measurement of activity. Some compounds exhibited substantial fold changes in IC 50 yet the overall potency was not high (e.g. MDMA and CYP1A2; thioTEPA and CYP2C8, etc). This article has not been copyedited and formatted. The final version may differ from this version. values after a 30 min preincubation of the inactivator, liver microsomes, and NADPH may represent a scaled-down empirical surrogate of a full determination of inactivation kinetic parameters, considering the excellent correlation to the k inact /K I ratio, an established measure of inactivation efficiency (Ernest, et al., 2005) . In a previous report it had been demonstrated that the magnitude of DDI could be reliably predicted for reversible inhibitors when the estimated unbound portal vein C max was used, along with reversible inhibition constants (Obach, et al., 2005) . However, it was observed that this approach was not generally accurate for compounds known to be mechanism based inactivators. Thus, IC 50 values generated after an inactivation preincubation (i.e. "shifted" IC 50 values) were used in equations 7 and 8 which had been previously demonstrated to yield accurate predictions of DDI for reversible inhibitors when combined with estimates of unbound portal vein C max values. Results are listed in Table 5 , and a plot of predicted DDI vs actual values from clinical studies is shown in Figure 4 of DDI greater than 2-fold would be made but the actual value was less than 2-fold (e.g. ticlopidine/theophylline and zileuton). Similar observations were made when the estimated unbound portal vein C max was used for [I] . Unbound systemic C max values generally provided the most accurate predictions. Geometric mean fold errors for predictions using total systemic C max , unbound systemic C max , and estimated unbound portal vein C max were 2.50, 1.64, and 2.63, 
DISCUSSION
Among scientists studying drug metabolism it has been a longstanding goal to develop methods whereby in vitro data can be used for making reliable predictions of various pharmacokinetic phenomena such as clearance and DDI. An increased understanding of the enzymes and transporters involved in drug metabolism and disposition has led to an increasing ability to make such predictions. Drugs that are known to cause increases in exposure to other drugs commonly cause these by reversible inhibition or irreversible inactivation of metabolizing enzymes. In previous reports, demonstrate an ability to predict DDI for those compounds that reversibly inhibit human CYP enzymes was demonstrated (Obach, et al., 2005 . However, in these reports, underpredictions of DDI for several drugs using reversible inhibition data were made, due to these compounds actually being irreversible inactivators of drug metabolizing enzymes. For individual drugs, others have shown that DDI caused by irreversible inactivation of CYP enzymes can be predicted (Galetin, et al., 2006; Obach, 2005, Wang, et al., 2004; Ito, et al., 2003; Yamano, et al., 2001; Mayhew, et al., 2000; Kanamitsu, et al., 2000) .
In these reports, the investigators have used various values for the input parameters such as enzyme degradation rate constants derived from animal or hepatocyte data. However, to date, the prediction of DDI caused by CYP inactivators for a comprehensive set of drugs has not been reported. In the present work, attempts to make DDI predictions for inactivators using a set of drugs that spans multiple CYP enzymes were made, albeit the number of drugs for which this can be done (particularly for non-CYP3A enzymes) is still limited compared to the set used to predict DDI for reversible inhibitors (Obach, et al., 2005) .
In the present report, a hierarchy of in vitro inactivation approaches was presented. It was demonstrated that a simple experiment that employs a single concentration of inactivator that is preincubated with human liver microsomes in the presence and absence of NADPH for 30 min prior to measurement of a CYP marker activity can distinguish irreversible inactivators from noninactivators (Table 2) . Such an experimental design can be employed in early stages of drug This Inactivators show a lower IC 50 when preincubated with NADPH, and the resulting "shifted" IC 50 could be useful for predicting the magnitude of a DDI when combined with the estimated unbound portal C max of the inactivator and inserted into equations used for predicting DDI for reversible inhibitors . While this approach is empirical, and the shifted IC 50 values measured would depend on elements of the experimental design (e.g. preincubation time, dilution factor, etc), it does appear to be a reasonable approach to making initial predictions of the magnitude of DDI when conducted in the manner described in this report. Furthermore, use of this approach can be rationalized by the excellent correlation observed between the "shifted" IC 50 and the k inact /K I value, the latter being an established measure of inactivator efficiency.
The use of k inact and K I in predicting DDI for inactivators has been the most frequently reported approach. In the present study, application of this approach was attempted across multiple known inactivators and seven human CYP enzymes. The complexity underlying predicting DDI for inactivators must be appreciated; there are multiple parameters that need to be considered, each with their own sources of uncertainty. Also, there are aspects of in vitro experimental design that can yield variability and inaccuracy. These have been discussed in a recent paper by Ghanbari, et al. (2006) . The four parameters that are most important to making accurate predictions of DDI caused by inactivators are (1) the in vivo rate of enzyme degradation, k deg , (2) the relevant in vivo concentration of the inactivator, [I], available to the target enzyme, (3) the in vitro inactivation kinetic parameters (K I and k inact ), and (4) the fraction of the clearance of the affected drug that is mediated by the inactivated enzyme. The first three input parameters are discussed below, while the importance of the fourth has been previously discussed (Ito, et al., 2005; . Furthermore, it must be kept in mind that the clinical drug interaction This article has not been copyedited and formatted. The final version may differ from this version. data used to test the accuracy of predictions from in vitro inactivation data is derived from reports that employed a variety of study designs each of which have influence on the magnitude of the interaction (e.g. timing of the dosing, etc.).
In previous reports, the value used for k deg for CYP enzymes frequently was a value derived from rat (k deg ≈ 0.0008/min; Mayhew, et al., 2000) . In the present work, values for k deg were utilized that were derived from modeling of the time course of reversal of DDI caused by induction or inactivation of CYP enzymes in human study subjects. The values obtained were substantially lower than the rat value, were within values reported in Ghanbari, et al. (2006) , and when used generally led to over-prediction of the magnitude of DDI (i.e. lower k deg leads to greater DDI). Actual measurements of CYP enzyme k deg values in humans in vivo are not obtainable with technology presently available, leaving this parameter as one important source of potential error in DDI predictions for inactivators.
The use of estimated unbound hepatic inlet concentrations of inhibitors occurring during the absorption phase, as surrogates for free concentrations in the liver, proved to be a reliable value for in vivo inhibitor concentration in prediction of DDI magnitude for reversible inhibition . Such a value has face validity as the target enzymes are in the liver (and for CYP3A in the gut as well), thus it is expected that this tissue, and hence the target CYP enzyme, would be exposed to considerably greater concentrations of inhibitor than those reflected by systemic concentrations. However, when employed for the prediction of DDI caused by inactivators, estimated free portal concentrations generally led to over-predictions of the magnitude of DDI (Table 6 ). Rather, use of the free systemic C max of the inactivator yielded the most accurate predictions of DDI when combined with inactivation data (Table 6 ). Although this was observed for the compounds examined in this report, continued testing of the use of free systemic C max for predicting DDI for CYP inactivators is warranted. An explanation for the discrepancy between the value for [I] that is most useful for DDI prediction for reversible inhibitors vs irreversible inactivators is not readily apparent and merits further exploration. The experimental design employed in inactivation experiments can have an impact on the measured parameters (Yang et al., 2005; Ghanbari, et al., 2006) . In the present studies, an approach was used wherein the inactivator was incubated with enzyme and cofactor for periods of time prior to dilution of the mixture into incubations in which the marker activity was measured.
A major advantage of such an approach includes limiting reversible competitive inhibition, due to dilution of the inactivator in the incubation where marker activity is measured and the use of saturating index substrate concentrations in the activity assay. Comparison of activities to incubations that were preincubated with NADPH in the absence of inactivator is important for CYP enzymes since reactive oxygen species that can inactivate the enzyme can be generated in the presence of NADPH and absence of inactivator or substrate. This phenomenon can be accounted for by including the k obs at [I] = 0 in the non-linear fitting of the k obs vs [I] relationship (e.g. Figure 2c ), as was done in this report. Use of linearized data to estimate inactivation kinetic parameters can undervalue this important factor. A disadvantage of using the dilution approach resides in the potential for inactivators to non-specifically bind to microsomal protein in the inactivation incubation since greater protein concentrations (i.e. >0.1 mg/ml) are needed. This factor was not accounted for in the present study, however correction for any non-specific binding would only cause the K I to decrease and lead to even greater over-predictions of DDI.
With the exception of CYP2C19, the protein concentrations used in inactivation incubations were still relatively low (≤0.3 mg/ml; Table 1) that cause marked DDI tend to reside toward the upper right while those that do not cause DDI reside in the lower left. Predictions of DDI could be made for those drugs for which inactivation kinetic data have been measured in this report but for which there are no in vivo DDI data, by judging whether they reside on the plot near the cluster of known perpetrators of DDI or known non-perpetrators of DDI. Thus, it would be expected that MDMA should cause DDIs of concern for CYP2D6 cleared drugs (point 6b on the plot) and thioTEPA should cause DDIs of concern for CYP2B6 cleared drugs (point 3a), whereas ticlopidine, thioTEPA, and MDMA should not cause interactions with drugs cleared by CYP3A, CYP2C19, or CYP1A2, respectively (points 5d, 3c, and 6a). Continued testing of the application of this contour plot is required to determine whether it is broadly applicable to aid inactivation DDI risk assessment for new molecular entities based on where they fall on the contour map relative to known clinically established DDI perpetrators and non-perpetrators.
In summary, the data presented in this report demonstrate that in vitro inactivation kinetic data for human CYP enzymes can be useful in predicting in vivo DDI, when combined with the systemic unbound concentration of inactivator, the fraction of the affected drug metabolized by the inactivated CYP, and estimates of in vivo degradation rates of enzyme. Uncertainty in the multiple parameters needed for these predictions must be appreciated. Additionally, some abbreviated experimental approaches that can identify mechanism-based inactivators were presented. These can be employed in early drug discovery research when the number of new compounds requiring investigation for this undesired property can exceed the capacity for conducting complete characterizations of inactivation kinetics. ThioTEPA  CYP2B6  -46  38  16  13  -50  32  Desethylamiodarone  CYP2C8  -21  30  36  -21  29  25  Tienilic Acid  CYP2C9  ---59  ----Ticlopidine  CYP2C19  21  43  --11  -35  19  MDMA  CYP2D6  25  25  ---59  --Paroxetine  CYP2D6  -----62  24  29  Diltiazem  CYP3A  ------37  43  Erythromycin  CYP3A  ------43  67  Ritonavir   c   CYP3A  --------Verapamil  CYP3A  ------49  63  Montelukast  none  --------a CYP3A(M) and CYP3A(T) refer to midazolam and testosterone hydroxylase activities, respectively. b A dash indicates that the decrease in activity was less than 15%, except for CYP2C19 which was <10%. c It should be noted that ritonavir demonstrates less than a 15% in activity with preincubation. This is likely due to the extremely potent reversible inhibition caused by this compound. The free fraction of furafylline in human plasma was unavailable in the scientific literature. A value of 0.39 was measured experimentally using ultrafiltration.
c The value for [I] in vivo used in the predictions was the unbound estimated portal vein C max as described in The free fraction of furafylline in human plasma was unavailable in the scientific literature. A value of 0.39 was measured experimentally using ultrafiltration. c Clinical interaction data used in this analysis represents the largest reported interaction for each inactivator. 
